Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 132,192,000
  • Shares Outstanding, K 2,550,000
  • Annual Sales, $ 16,611 M
  • Annual Income, $ 5,636 M
  • 36-Month Beta 0.63
  • Price/Sales 8.26
  • Price/Cash Flow 22.19
  • Price/Book 17.79

Price Performance

See More
Period Period Low Period High Performance
1-Month
48.77 +7.12%
on 11/09/17
52.32 -0.15%
on 11/24/17
+1.92 (+3.82%)
since 10/24/17
3-Month
45.17 +15.65%
on 09/05/17
52.32 -0.15%
on 11/24/17
+6.62 (+14.51%)
since 08/24/17
52-Week
31.91 +63.71%
on 11/25/16
52.32 -0.15%
on 11/24/17
+20.67 (+65.47%)
since 11/23/16

Most Recent Stories

More News
Psoriatic Arthritis - Pipeline Review, H2 2017 - Research and Markets

The "Psoriatic Arthritis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis...

NVO : 52.24 (+0.77%)
JNJ : 138.01 (+0.52%)
AGN : 173.53 (-0.74%)
ABBV : 94.72 (+0.26%)
AMGN : 170.12 (+0.09%)
PFE : 35.49 (+0.17%)
FSNUF : 78.7560 (-1.37%)
LLY : 84.03 (+0.42%)
RIGL : 4.25 (unch)
NHKFF : 14.4000 (unch)
ACRS : 23.27 (+0.65%)
GLPG : 92.23 (+0.30%)
UCBJF : 72.7800 (+3.25%)
Health Canada approves Victoza® as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease.

Novo Nordisk announced today that Health Canada has approved a product monograph update for Victoza(®) (liraglutide). Victoza(®) is now approved to reduce the incidence of cardiovascular (CV) death in...

NVO : 52.24 (+0.77%)
Highlights to be presented at Novo Nordisk's Capital Markets Day 2017

Bagsvaerd, Denmark, 21 November 2017 - Novo Nordisk will today host a Capital Markets Day where the company will provide updates on its R&D and commercial strategy as well as current market dynamics.

NVO : 52.24 (+0.77%)
Roche's (RHHBY) Hemophilia A Drug Receives FDA Approval

Roche (RHHBY) hematology portfolio got a boost when the FDA approved Hemlibra (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with...

NVO : 52.24 (+0.77%)
SHPG : 147.86 (-1.28%)
ABBV : 94.72 (+0.26%)
RHHBY : 31.6000 (-0.19%)
The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel

The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel

TGT : 55.88 (-2.80%)
HUM : 240.51 (+0.93%)
NVO : 52.24 (+0.77%)
TOT : 56.43 (+0.57%)
XEL : 50.71 (+0.36%)
Top Analyst Reports for TOTAL S.A., Humana & Novo Nordisk

Top Analyst Reports for TOTAL S.A., Humana & Novo Nordisk

TGT : 55.88 (-2.80%)
HUM : 240.51 (+0.93%)
A : 69.36 (+0.98%)
NVO : 52.24 (+0.77%)
TOT : 56.43 (+0.57%)
XEL : 50.71 (+0.36%)
J&J Presents Positive New Data for Diabetes Drug Invokana

Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.

NVO : 52.24 (+0.77%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
LLY : 84.03 (+0.42%)
Diabetes Community Awakens Important Conversation about Hidden Problem: Hypoglycemia

Dr. Roberta Bondar shares personal anecdotes of time alone in the dark in space to drive awareness of nighttime hypoglycemia

NVO : 52.24 (+0.77%)
Pre-Market Technical Recap on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, United Therapeutics, and Depomed

If you want a Stock Review on SGYP, NVO, UTHR, or DEPO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com redirects investors' attention...

NVO : 52.24 (+0.77%)
SGYP : 1.90 (unch)
UTHR : 125.01 (-0.32%)
DEPO : 6.26 (-0.63%)
Anthony Anderson, Star of ABC's "black-ish," Partners with Novo Nordisk to Launch "Get Real About Diabetes(TM)"

Anthony Anderson, star of ABC's hit comedy "black-ish," wants to help people get real about diabetes. Today on World Diabetes Day, he kicks off "Get Real About Diabetes(TM)," a collaboration with Novo...

NVO : 52.24 (+0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 52.57
1st Resistance Point 52.40
Last Price 52.24
1st Support Level 51.99
2nd Support Level 51.75

See More

52-Week High 52.32
Last Price 52.24
Fibonacci 61.8% 44.52
Fibonacci 50% 42.11
Fibonacci 38.2% 39.71
52-Week Low 31.91

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart